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Abstract: The main objective of this study was to evaluate the prevalence of human immunodeficiency
virus/acquired immunodeficiency syndrome (HIV/AIDS), hepatitis C virus (HCV) and hepatitis B
virus (HBV) and their co-infections among people who inject drugs (PWID) and female sex workers
(FSWs). Data sources were searched from January 2008 to October 2018 in different databases.
Data were analyzed in Stata 16 software using the Metaprop command. The results showed that the
prevalence of HIV, HCV and HBV among PWID was 15%, 60% and 6%, respectively. The prevalence
of HIV, HCV and HBV among FSWs was 5%, 1% and 3%, respectively. The prevalence of HIV/HCV,
HIV/HBV, HCV/HBV and HIV/HCV/HBV co-infections among PWID was 13%, 2%, 3% and 2%,
respectively. The prevalence of HIV/HCV and HIV/HBV co-infections among FSWs was 3% and
1%, respectively. The results show that the prevalence of HCV and HIV infections in PWID and the
prevalence of HIV in FSWs is higher than their prevalence in the general population. Interventions for
the prevention of HIV and HCV in PWID appear to be poor, and may not be sufficient to effectively
prevent HIV and HCV transmission.
Keywords: human immunodeficiency virus (HIV); hepatitis C virus (HCV); hepatitis B virus (HBV);
people who inject drugs (PWID); female sex workers (FSWs); Co-infection
1. Introduction
According to a World Health Organization (WHO) report in 2018, there are approximately
38 million people living with HIV/AIDS in the world, the largest number being in Africa,
with 25.7 million [1]. The WHO’s goal is to identify 90% of HIV patients, treat 90% of those identified
and virally suppress 90% of those treated by 2020 [2]. Hepatitis C virus (HCV) and hepatitis B virus
(HBV) have affected 71 million and 257 million people worldwide, which can lead to cirrhosis and liver
cancer, respectively. Removing these viruses, which requires significant economic and sanitary capital,
will prevent more than 1.2 million deaths worldwide annually [3,4]. HCV has the highest prevalence
in the Eastern Mediterranean region, followed by the European region, with a prevalence of 2.3% and
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1.5%, respectively. It varies from 0.5% to 1% in other areas. HBV is most prevalent in the Western Pacific
and African regions, with values of 6.2% and 6.1%, respectively. The lowest prevalence is reported
in the US, with a value of 0.7% [5]. Viral hepatitis elimination program has been adapted by WHO
in 2016 [6]. In line with this global program, several countries are working towards this elimination
platform [7]. In this program, engagement of high-risk groups and marginal populations has been
highlighted [8,9]. The efficient implementation of prevention and control measures incorporated in this
program, requires detailed insight on the epidemiology of hepatitis viruses and other viral infectious
agents circulating in these cohorts [9].
People who inject drugs (PWID) and female sex workers (FSWs) are key populations for
blood-borne viral infections (BBVI), including HIV, HCV and HBV. PWID are usually infected
through shared needles, syringes and other infected injection equipment, as well as other high-risk
behaviors [10]. There are an estimated 15.6 million PWID aged 15–64 years worldwide. It is said that
23% of the new HCV cases and 33% of the annual HCV deaths are related to PWID [11,12]. According
to the WHO report in 2018, HIV prevalence in PWID is estimated to be from less than 1.8% to 13.5%,
but viral hepatitis has not been reported in many countries. HBV is 0.7% in some of these countries,
including Afghanistan, Germany and Nepal, and 7.3% in Azerbaijan, and HCV is less than 7% in some
countries, including Germany, Afghanistan and Madagascar, and more than 60% in Kazakhstan [13].
FSWs are also more exposed to high-risk behaviors, especially through sex. A study in a region
with a high prevalence of HIV in India stated that about 77.5% of FSWs had drug injection history,
and that they were at a higher risk of BBVI than those without drug injection. The prevalence of HIV
in FSWs worldwide ranges from less than 1.4% to over 11%. The prevalence of viral hepatitis is not
high in FSWs, but WHO reports that the prevalence of HBV in FSWs ranges from less than 0.3% in
Brazil to over 3.6% in Peru, and hepatitis C prevalence ranges from less than 1.9% in Brazil to 6.2%
in Kazakhstan in the same group. In fact, HIV is more prevalent among FSWs than HBV and HCV
infections [14–16]. The prevalence of HIV is 22 times higher among PWID and 21 times higher among
sex workers (SWs) than the general population. In 2018, about 54% of new HIV cases occurred among
key populations and their sexual partners [17].
In patients co-infected with two or three HIV, HCV and HBV infections, HIV-induced
immunodeficiency increases the likelihood of HBV and HCV persistence, and hepatotoxicity associated
with anti-HIV treatment can worsen HBV-related liver diseases or HCV persistence. Evidence suggests
that HIV infection increases the risk of HCV- and HBV-associated hepatocellular carcinoma. On the
other hand, liver diseases associated with chronic HBV and HCV are leading to increased mortality and
complications in HIV patients [18,19]. Adverse drug reactions (ADRs) related to antiretrovirals (ARVs)
are higher in HIV patients co-infected with HBV or HCV than in HIV-monoinfected patients [20].
The purpose of this study was to conduct a systematic review and meta-analysis to estimate
the prevalence of HIV (anti-HIV), HCV (anti-HCV), HBV (HBsAg) and their co-infections among
PWID and FSWs, as separated by WHO geographical areas in the general population of these groups.
The aim is to understand the current situation, in order to make better decisions regarding prevention,
identification and treatment.
The protocol of this study had been registered in the International Prospective Register of
Systematic Reviews (PROSPERO) (CRD42018115115).
2. Results
2.1. Search Results
As showed in Figure 1, 5631 articles were found in the original search. After the removal
of duplicate data, 2810 articles were selected for screening. After reviewing the title and abstract,
408 articles were selected for full text study. A total of 291 articles were excluded for various
reasons, including inappropriate study design (121), failure to report prevalence (68), irrelevant
target group (91), lack of proper testing (9) and non-originality (2). Eventually, after qualitative
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evaluation of data, 117 articles that had reported 161 records of HIV, HCV, HBV prevalence and
their co-infections (HIV/HCV, HIV/HBV, HCV/HBV, HIV/HCV/HBV) among PWID and FSWs were
analyzed. The characteristics of the studies are shown in Table 1. A total of 26 papers with 40 records
had been published in the South-East Asia region, 25 papers with 32 records in the Americas region,
21 papers with 28 records in the Europe region, 17 papers with 19 records in the Africa region, 15 papers
with 18 records in the Eastern Mediterranean region and 13 articles with 24 records in the Western
Pacific region. A total of 89 papers with 119 records had been conducted on PWID and 33 papers with
42 records on FSWs.
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Table 1. The characteristics of studies which entered into meta-analysis.
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2.2. Reports of Prevalence
2.2.1. Prevalence of HIV among PWID and FSWs
A total of 99 articles with 133 records and a sample size of 979,659 reported HIV prevalence
in PWID and FSWs, of which 74 articles with 95 records were on PWID and 29 articles with
38 records were on FSWs. The overall prevalence of HIV among PWID was estimated to be 15%
(95% CI: 12–18%, p = 0.00, I2 = 99.37%) and 5% among FSWs (95% CI: 4–5%, p = 0.00, I2 = 99.41%)
(Supplementary Figures S1 and S2, Table 2).
Table 2. The prevalence of HIV, HCV, HBV and their co-infections among PWID and FSWs by regions
of the World Health Organization (WHO); 2008–2018.
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2.2.2. Prevalence of HCV among PWID and FSWs
A total of 99 articles with 130 records and a sample size of 924,516 reported HCV prevalence
in PWID and FSWs. A total of 76 papers with 101 records had been conducted on PWID and
24 papers with 29 records on FSWs. The overall prevalence of HCV in PWID and FSWs was 60%
(95% CI: 55–64%, p = 0.00, I2 = 99.54%) and 1% (95% CI: 1–2%, p = 0.00, I2 = 97.04%), respectively
(Supplementary Figures S3 and S4, Table 2).
2.2.3. Prevalence of HBV among PWID and FSWs
A total of 53 articles with 64 records and a sample size of 35,007 reported HBV prevalence
in PWID and FSWs. A total of 37 papers with 44 records had been conducted on PWID and
18 papers with 20 records on FSWs. The overall prevalence of HBV in PWID and FSWs was 6%
(95% CI: 5–8%, p = 0.00, I2 = 94.84%) and 3% (95% CI: 1–5%, p = 0.00, I2 = 95.37%), respectively
(Supplementary Figures S5 and S6, Table 2).
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2.2.4. Prevalence of Co-infections of HIV, HCV and HBV among PWID and FSWs
A total of 50 articles with 52 records and a sample size of 48,773 reported co-infection of HIV/HCV
in PWID and FSWs. A total of 41 papers with 43 records had been conducted on PWID and nine
papers with nine records on FSWs. The overall prevalence of HIV/HCV in PWID and FSWs was 13%
(95% CI: 9–18%, p = 0.00, I2 = 99.36%) and 3% (95% CI: 0–9%, p = 0.00, I2 = 97.72%), respectively
(Supplementary Figures S7 and S8, Table 2).
A total of 18 articles with 23 records and a sample size of 12,361 reported co-infection of HIV/HBV
in PWID and FSWs, of which 12 articles with 14 records were on PWID and seven articles with
nine records were on FSWs. The overall prevalence of HIV/HBV in PWID and FSWs was 2%
(95% CI: 1–3%, p = 0.00, I2 = 93.26%) and 1% (95% CI: 0–3%, p = 0.00, I2 = 93.74%), respectively
(Supplementary Figures S9 and S10, Table 2).
A total of 14 articles with 14 records and a sample size of 10,844 reported co-infection of HCV/HBV
in PWID and FSWs, of which 13 articles with 13 records were on PWID and one article with one
record was on FSWs [31]. The overall prevalence of HCV/HBV in PWID was 3% (95% CI: 1–5%,
p = 0.00, I2 = 92.39%) (Supplementary Figure S11, Table 2).
A total of nine articles with nine records and a sample size of 3849 reported co-infection of
HIV/HCV/HBV in PWID, but no articles reported this co-infection in FSWs. The overall prevalence
of co-infection of HIV/HCV/HBV among PWID was estimated to be 2% (95% CI: 1–3%, p = 0.00,
I2 = 75.19%) (Supplementary Figure S12, Table 2).
2.3. Subgroup Analysis by Regions of WHO
Subgroup analysis based on WHO regions is shown in Table 2. The highest prevalence of HIV
in PWID is in the Africa region (24%) and the lowest prevalence is in the Eastern Mediterranean
region (8%). The highest prevalence of HIV in FSWs is in the Africa (19%) and South-East Asia (18%)
regions and the lowest prevalence is in Eastern Mediterranean (0%) and Western Pacific (1%) regions.
The highest prevalence of HCV in PWID is in the Western Pacific (75%) and the lowest prevalence is in
Africa (38%). The highest prevalence of HCV in FSWs is in Africa (9%) and the lowest prevalence is in
Western Pacific and the Americas regions (1% each). The highest prevalence of HBV in PWID is in
South-East Asia (9%) and the lowest prevalence is in the Americas and Eastern Mediterranean regions
(1% each). The highest prevalence of HBV in FSWs is in Africa (5%) and South-East Asia (4%) regions
and the lowest prevalence is in the Americas and Eastern Mediterranean (1% each).
The highest prevalence of HIV/HCV in PWID is in the South-East Asia, Africa and Europe regions
(17%, 16% and 16%, respectively) and the lowest prevalence is in the Eastern Mediterranean region
(8%); the highest prevalence in FSWs is in Africa (23%) and the lowest prevalence is in the Americas
and South-East Asia regions (0% and 1%, respectively). The prevalence of HIV/HBV in PWID was
estimated to be 2% in South-East Asia and 1% in Africa and the Eastern Mediterranean. The highest
prevalence of HIV/HBV in FSWs was in Africa with 7% and the lowest prevalence was in South-East
Asia with 1%. The prevalence of HCV/HBV in PWID in the South-East Asia and Eastern Mediterranean
was 3% each, and the prevalence of HIV/HCV/HBV in PWID was 2% in South-East Asia and 1% in
both Africa and the Eastern Mediterranean (Table 2).
2.4. Meta-Regression
Meta-regression results on heterogeneity of studies showed that sample size had a significant
effect on the prevalence of HIV, HCV, HBV, HIV/HCV and HCV/HBV among PWID and HIV, HCV and
HBV among FSWs, but the mean age of study participants has no significant effect (Table 3).
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Table 3. The results of met-regression on heterogeneity of pooled estimations.
Study Population Coefficient [95% ConfidenceInterval] Standard Error t p > t
HIV
age 0.27 −0.12 0.67 0.19 1.39 0.17
Sample size 0.19 0.15 0.23 0.02 9.47 0.00
HCV
age 0.07 −0.29 0.45 0.18 0.43 0.67
Sample size 0.59 0.54 0.64 0.02 23.96 0.00
HBV
age 0.05 −0.12 0.24 0.08 0.69 0.5
Sample size 0.06 0.04 0.09 0.01 6.26 0.00
HIV/HCV
age 0.18 −0.30 0.66 0.22 0.81 0.43
Sample size 0.16 0.12 0.20 0.02 7.76 0.00
HIV/HBV
age −0.15 −0.58 0.27 0.17 −0.90 0.40
Sample size 0.02 0.00 0.04 0.01 2.02 0.06
HBV/HCV
age 0.00 −0.51 0.50 0.18 −0.01 0.99
Sample size 0.04 0.00 0.07 0.01 2.75 0.02
HIV/HCV/HBV
age 0.04 −0.89 0.98 0.61 0.7 0.65
PWID
Sample size 0.00 −0.01 0.01 0.00 0.03 0.97
HIV
age −0.38 −1.16 0.38 0.35 −1.10 0.29
Sample size 0.10 0.06 0.14 0.02 5.27 0.00
HCV
age −0.01 −0.38 0.34 0.15 −0.11 0.91
Sample size 0.05 0.01 0.08 0.01 2.71 0.01
HBV
age 0.23 −0.10 0.57 0.14 1.66 0.14
Sample size 0.05 0.02 0.08 0.01 3.65 0.00
HIV/HCV
age 0.12 −1.55 1.80 0.13 0.96 0.51
Sample size 0.06 −0.02 0.16 0.03 1.73 0.13
HIV/HBV
FSWs
Sample size 0.03 −0.03 0.10 0.02 1.61 0.20
2.5. Publication Bias
Egger’s test results were significant for HIV prevalence among PWID and FSWs (p = 0.00),
HCV among FSWs (p = 0.009), HBV among PWID and FSWs (p = 0.00), HIV/HCV among PWID
(p = 0.00), HIV/HCV among FSWs (p = 0.029), HIV/HBV among PWID and FSWs (p = 0.003), and HCV/
HBV among PWID (p = 0.008), pointing to publication bias. However, it was not significant for
HIV/HCV/HBV prevalence (p = 0.432) and HCV among PWID (p = 0.078) indicating no publication bias.
3. Discussion
This systematic review and meta-analysis examined the prevalence of HIV, HCV, HBV and their
co-infections among PWID and FSWs worldwide, and the results were shown by different WHO
regions. The prevalence of HIV in PWID and FSWs was 15% and 5%, respectively. That means one of
seven PWID and one of 20 FSWs get infected with HIV, with the highest prevalence in PWID being
in Africa (24%), South-East Asia (22%) and Europe (12%), and in FSWs being in Africa (19%) and
South-East Asia (18%). The number of people living with HIV worldwide in 2017 was estimated to be
36.8 million [145]. HIV is most likely transmitted through unprotected sex and syringes and needles
used for injections. A total of 69.5% of HIV infection in the general population occurs through needle
sharing and 10% through unprotected sex [146–148]. In a meta-analysis study in 2017, the prevalence
of HIV among PWID worldwide was reported to be 17.8%, and the largest population under study
was from sub-Saharan Africa. A total of 95% of new HIV cases were among the key populations in the
Middle East and North Africa (MENA) [13]. In a 2019 study, the prevalence of HIV in PWID was 21%
Pathogens 2020, 9, 432 15 of 27
in Africa; in another study, HIV incidence in PWID in the MENA region was significant, with 75% of
new cases occurring in PWID and their sexual partners [149,150]. The meta-analysis by Leung et al.,
in 2019, also estimated the highest prevalence of HIV in Africa and Asia, which is consistent with
the results of our study [151]. The prevalence of HIV in Brazilian FSWs was 5%, and in part-time sex
workers in Burkina Faso it was 6.5% [31,152].
The prevalence of HCV in PWID and FSWs was 60% and 1%, respectively. That means that almost
one in every two PWID has HCV, with the highest prevalence of HCV in PWID being in the Western
Pacific, the Americas and the Eastern Mediterranean, with 75%, 64% and 60%, respectively, and the
lowest being in Africa (38%); the highest prevalence in FSWs is in Africa (9%), and the lowest prevalence
is in the Americas and Western Pacific (1% each). In a 2007 meta-analysis study, the prevalence of HCV
in PWID worldwide was estimated to be 50% [153]. In another study published by Nelson et al. in
2011, the prevalence of HCV in PWID was reported to be 60–80% in 25 countries and over 80% in
12 countries, with approximately 10 million PWID suffering from HCV, China and the US having the
largest population [154]. Another meta-analysis study estimated the lowest prevalence of HCV was in
the Middle East, North Africa, East and South-East Asia [152]. Worldwide, it is estimated that 14 million
PWID are at risk for HCV exposure from contaminated blood. In 2011, the prevalence of hepatitis
C in PWID worldwide was estimated to be 67%, the highest prevalence being in Eastern Europe
(2.3 million) and East and South-East Asia (2.6 million) [154]. Degenhardt et al. (2017) reported a 52.3%
prevalence of HCV among PWID worldwide [11]. In another European Union study, the prevalence
of HCV among general population was estimated to be 0.54% to 1.50% in 2019, with the highest
prevalence in PWID being in the range of 7.9–82% [155]. In a study in Brazil, the prevalence of hepatitis
C in FSWs was estimated to be 0.9% [31]. The relatively high prevalence of needle/syringe sharing,
low condom use, high levels of sex with sex workers, homosexual sex between men, and selling
sex, indicate high-risk behaviors associated with HIV and HCV prevalence in different regions [156].
Another parameter influencing the prevalence and natural history of HCV infection is the host immune
response-related genetics such as IFNL3/4 polymorphisms which impact the spontaneous clearance of
HCV, and it was also observed that the genotypes associated with favorable outcome has different
prevalence in ethnic groups [157,158].
In this study, the prevalence of HBV in PWID and FSWs was 6% and 3%, respectively, with the
highest prevalence in PWID being in South-East Asia (9%) and Africa and the Eastern Mediterranean
(5% each), and the lowest prevalence being in the Americas and Western Pacific (1% each). Moreover,
the highest prevalence in FSWs was in Africa (5%) and South-East Asia (4%), and the lowest prevalence
was in the Americas and Eastern Mediterranean (1% each). Nearly 3.6% of the world’s population
(257 million people) have chronic hepatitis B, with a prevalence of 0.01–2% in the UK, the US, Canada,
Western Europe, and Japan, and over 8% in most sub-Saharan areas in Africa and some countries
in the Western Pacific region [5,159]. In high- and middle-income countries, HBV transmission is
more perinatal and horizontal. In low-income countries, however, transmission occurs through drug
injection and high-risk sexual behaviors [160]. Asia and Africa have the highest HBV endemicity,
but highly effective vaccination programs in some countries have pushed the pattern towards moderate
or low endemicity. Therefore, China is currently the only country in Asia where HBV is of paramount
importance. Countries with moderate endemicity include India, Korea, the Philippines, Taiwan and
Thailand. Countries with low endemicity include Japan, Pakistan, Bangladesh, Singapore, Sri Lanka
and Malaysia. Most countries in Africa have high endemicity, with the exception of Tunisia and
Morocco, which have moderate endemicity [161]. HBV vaccination is effective in reducing and
eliminating HBV by 2030. According to the WHO, in 2017, 97% of blood donors were screened for
HBV, but there are gaps in the program and strategies have been suggested to resolve the problems,
including reducing insecure injections (it has reduced from 39% in 2000 to 5% in 2010), and safer sex
practices, such as minimizing the number of sexual partners and using protection (condoms). On the
other hand, according to WHO, 80% of people with hepatitis live without prevention, testing and
treatment [5]. In a study from Germany, the coverage of three HBV vaccines was 58% for drug users,
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one of the influencing factors being injection drug use [162]. The prevalence of HBsAg in PWID in the
study by Nelson et al is estimated to be 5–10% in 21 countries and over 10% in 10 other countries with
a population of 1.2 million [153]. In a 2017 study, the prevalence of HBV among PWID worldwide was
9.1%. In another study, its prevalence was reported to be 5% in Africa [149,154].
The prevalence of HIV/HCV in PWID and FSWs was 13% and 3%, respectively, with the highest
prevalence in PWID being in South-East Asia (17%), Africa and Europe (16% each), and the lowest in
Eastern Mediterranean (8%); and the highest prevalence in FSWs being in Africa, and the lowest being
in the Americas and South-East Asia (23%, 0% and 0%, respectively). The prevalence of HIV/HBV in
PWID and FSWs was 2% and 1%, respectively, and the prevalence of HCV/HBV and HIV/HCV/HBV in
PWID was 3% and 2%, respectively. The study by Larney et al. found a positive association between the
high prevalence of anti-HCV and the prevalence of HIV in PWID worldwide [163]. Co-infection with
viral hepatitis in HIV-positive patients may worsen the prognosis [164]. HBV reactivation is observed
in patients with HBV/HCV co-infection during HCV treatment (direct acting antivirals (DAA)) or
afterwards [165].
Strength and Limitations
Previous systematic review studies have investigated the prevalence of HIV, HCV and HBV in
PWID worldwide, but we have investigated the prevalence of these infections and their co-infections
in the high-risk groups PWID and FSWs as distinguished by geographical areas. One limitation of
this study is the changing sensitivity of HIV, HCV and HBV diagnostic tests over time, therefore,
the results of the 2018 surveys may be different from 2008. In this study, all the reviewed articles
had used anti-HCV serology test to detect HCV, which does not differ between past and present
infections. The articles reporting HCV-RNA were scarce and excluded. Another limitation of our study
is the high heterogeneity in studies. As the analysis was performed in different geographical areas,
the heterogeneity may be due to different inclusion and exclusion criteria (e.g., type of drug, minimum
duration of injectable drug use, sampling location (prison, the Behavioral Disease Counseling Center,
MMT Center, homeless people), frequency of sex during a specific time, number of sexual partners and
condom use).
4. Materials and Methods
4.1. Search Strategy
This systematic review and meta-analysis was designed based on the Preferred Reporting Items
for Systematic Reviews and Meta-Analyzes (PRISMA). Information sources from January 2008 to
October 2018 were searched. Databases including PubMed, Scopus, Web of Science, Embase, Ovid,
WHO and Google Scholar were searched, to find out the prevalence of HIV, HCV, HBV and their
co-infections. The databases were searched using MESH keywords and the Boolean logic (AND,
OR and NOT). The keywords included “Human Immunodeficiency Virus”, “HIV”, “Hepatitis C”,
“HCV” “Hepatitis B”, “HBV”, “PWID”, “IDU”, “IVDU”, “FSWs” and “Co-infection”.
4.2. Study Selection and Data Extraction
Cross-sectional studies published in English that assessed anti-HIV, anti-HCV and HBsAg were
selected. The studies that did not have a specific serology test to detect infections, those in which the
prevalence rate was based on self-reports, the ones that used HBsAb, HBcAb, HBeAg and HBeAb
tests to detect HBV and used HCV-RNA to detect HCV, and non-cross-sectional studies (case reports,
reviews, case-control and cohort studies) were excluded.
After consulting with experts, two authors (RR and YM) extracted the data from the original articles.
Extracted data include: (1) name of first author, (2) date of publication, (3) date of study, (4) country,
(5) study subjects, (6) age of patients, (7) sample size, (8) method of sampling, (9) prevalence of HIV
among PWID and FSWs, (10) prevalence of HCV among PWID and FSWs, (11) prevalence of HBV among
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PWID and FSWs, (12) prevalence of HIV/HCV among PWID and FSWs, (13) prevalence of HIV/HBV
among PWID and FSWs, (14) prevalence of HCV/HBV among PWID and FSWs, (15) prevalence of
HIV/HCV/HBV among PWID and FSWs.
All the steps ranging from searching to extracting data were independently performed by two
researchers. In case of disagreement between the two, the problem was solved by referring to the
article, discussing the problem and, if necessary, seeking help from a third reviewer (Kappa statistic for
agreement for quality assessment; 0.75).
4.3. Quality Assessment
In this study, the Newcastle-Ottawa Quality Assessment Scale (NOS) checklist for cross-sectional
studies was used to evaluate possible bias and quality of studies. This checklist was completed by
two people. The quality of studies were judged based on such aspects as selection, comparability and
outcome using the “star” rating system. Scores ranged from 0 stars (worst case) to 9 stars (best case).
Studies with a score of 0–4 were categorized as low quality, 5–7 as moderate and more than 7 as
high quality.
4.4. Statistical Analysis
Meta-analysis was performed on the eligible data to determine the prevalence of HIV/HCV,
HIV/HBV, HCV/HBV, HIV/HCV/HBV, HIV, HCV and HBV in PWID and FSWs. A chi-square test was
used to investigate the heterogeneity of the studies. The heterogeneity results from random-effects
model were used to analyze the data at 95% confidence level. The MetaProp command was used to
estimate the prevalence.
Egger’s statistical test and funnel plot were used to evaluate publication bias. Subgroup analysis
was performed to investigate any qualitative confounding factors that may influence the prevalence of
the disease. Subgroup analysis was conducted for the two high risk groups of PWID and FSWs in
WHO geographical areas. Meta-regression was performed for mean age and sample size. All two-way
statistical tests were considered with α = 0.05. Meta-analysis was performed in STATA 16.
5. Conclusions
The results show that the prevalence of HCV and HIV infections in PWID, and the prevalence
of HIV in FSWs are higher than in the general population. The results indicate that the coverage of
interventions for HIV and HCV prevention in PWID appear to be poor, and may not be sufficient to
effectively prevent HIV and HCV transmission. Additionally, the lack of political commitment and, as a
result, inadequate investment, reluctance to address sensitive issues related to young people’s sexual
and reproductive needs and rights, and issues related to key populations and harm reduction, and a
lack of systematic prevention implementation, even with regard to policy, are three interconnected
reasons that seem to underpin the failure to implement effective programs at scale. Increasing the
interventions for PWID and FSWs, such as HBV vaccination for the prevention of HBV, and the use
of harm reduction programs, such as reducing the number of sexual partners per person, condom
distribution, the use of clean needles and syringes, opiate substitution therapy (e.g., methadone) and
the treatment of people living with HIV to reduce viral load and prevent onward transmission of
HCV, are still a top priority in stopping the HIV and HCV epidemics. For HCV patients, education
and counselling on options for care and treatment; immunization with the hepatitis A and B vaccines
to prevent co-infection from these hepatitis viruses, and to protect their liver; early and appropriate
medical management, including antiviral therapy; and regular monitoring for early diagnosis of
chronic liver disease are necessary. Key population should be regularly monitored and screened for
these infections and their associated infections.
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